Nyrada Inc. posted a significant $2.46 million loss for H1 FY25, driven by increased R&D spend, while advancing its lead drug NYR-BI03 into first-in-human trials following regulatory approval.
Macarthur Minerals Limited reported a comprehensive loss of AUD 252,771 for Q4 2024, marking a sharp reversal from the prior year's profit. The company is navigating reduced exploration spending and strategic asset sales while facing ongoing funding challenges.
Ten Sixty Four Limited has revealed a staggering net loss of US$43 million for the year ended June 2024, alongside a sharp 94% revenue decline and a modified audit opinion, raising fresh questions about its financial stability.